All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Old Standards Are Revisited in HER2+ Early-Stage Breast Cancer

February 23rd 2023

As targeted agents for various levels of HER2 expression have demonstrated dynamic interoperability and efficacy, the prognosis for HER2-positive disease has improved.

TTFields With Chemotherapy Under Investigation in Locally Advanced Pancreatic Cancer

February 23rd 2023

Tumor treating fields concomitant with gemcitabine and nab-paclitaxel is being compared with chemotherapy alone in the frontline treatment of patients with aggressive, locally advanced pancreatic cancer as part of the phase 3 PANOVA-3 trial.

EU Approves Durvalumab/Tremelimumab Combo for Advanced Lung, Liver Cancers

February 22nd 2023

The European Union has approved durvalumab plus tremelimumab-actl for first-line treatment of advanced or unresectable hepatocellular carcinoma and in combination with platinum-based chemotherapy in metastatic non–small cell lung cancer, according to a news release from AstraZeneca.

Acalabrutinib Tablet Formulation Approved in Europe for Chronic Lymphocytic Leukemia

February 22nd 2023

The European Commission has approved the tablet formulation of acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia.

Nab-sirolimus Under Investigation in TSC1/TSC2-Mutated GI Solid Tumors

February 22nd 2023

James J. Harding, MD, describes the GI tumors where TSC1 or TSC2 alterations can arise, how the mechanism of action of nab-sirolimus may help fulfill an unmet need in this population, and the importance of using genetic testing to identify patients with mutations in TSC1, TSC2, or other genes to drive targeted treatment.

Dr. Anand P. Jillella of Georgia Cancer Center Named a Cancer Care “Trailblazer”

February 22nd 2023

Anand P. Jillella, MD, has been selected as one of 20 Georgia “Trailblazers” in cancer care by the Georgia Center for Oncology Research and Education.

FDA Grants Priority Review to Elranatamab in Relapsed/Refractory Myeloma

February 22nd 2023

The FDA has granted a priority review to the biologics license application for elranatamab for the treatment of patients with relapsed/refractory multiple myeloma.

Aileron Terminates Phase 1b Trial Evaluating ALRN-6924 in P53-mutant Breast Cancer

February 22nd 2023

Despite treatment with the chemoprotective agent ALRN-6924, patients with p53-mutated breast cancer receiving neoadjuvant or adjuvant therapy with docetaxel, doxorubicin, and cyclophosphamide failed to meet the trial’s primary and secondary end points of duration and incidence of severe neutropenia in cycle 1 and incidence of chemotherapy-induced alopecia, respectively.

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22nd 2023

For patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-related adverse effect.

Zanidatamab Plus Chemo Displays Early Activity in HER2+ Metastatic Gastroesophageal Adenocarcinoma

February 22nd 2023

The combination of zanidatamab and standard chemotherapy demonstrated activity when used as a first-line treatment for patients with HER2-positive metastatic or advanced gastroesophageal adenocarcinoma.

New Options Poised to Make a Splash in Metastatic Prostate Cancer

February 21st 2023

Matthew Rettig, MD, discusses emerging treatment options for patients with stage IV metastatic prostate cancer and highlights key data from clinical trials in the space.

PSMA-PET Highlights Evolution of Molecular Imaging in Prostate Cancer

February 21st 2023

Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.

Combination Regimens May Expand PARP Inhibitor Efficacy in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.

New Technology Advances Prostate Cancer Care But Questions Linger

February 21st 2023

Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.

Toripalimab Plus Chemotherapy Meets PFS End Point in PD-L1+ TNBC

February 21st 2023

Toripalimab plus nab-paclitaxel demonstrated a significant improvement in progression-free survival compared with placebo and nab-paclitaxel in PD-L1–positive patients with stage IV or recurrent/metastatic triple-negative breast cancer.

Multidisciplinary Discussions Move the Needle Toward Innovative Prostate Cancer Care

February 21st 2023

Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .

Nivolumab Plus Salvage Immunotherapy Leads to High TFS Rates in Advanced RCC

February 21st 2023

Nivolumab monotherapy, plus salvage nivolumab plus ipilimumab for progressive disease, resulted in high treatment-free survival rates in patients with previously untreated advanced clear cell renal cell carcinoma.

MHRA Approves Selinexor Plus Bortezomib/Dexamethasone for Multiple Myeloma Following 1 Prior Therapy

February 21st 2023

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted full marketing authorization for selinexor in combination with bortezomib and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.

Jaime Merchán, MD, Named Sylvester’s Translational and Clinical Oncology Research Program Co-Leader

February 21st 2023

Jaime Merchán, MD, is the new Translational and Clinical Oncology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System.

The Implications of the Underappreciated, Evolving View of Cancer as a Chronic Illness

February 21st 2023

Successful manipulation of the immune system to achieve regression of cancer, long an unfulfilled goal of oncologic investigation, is an ever-increasing reality in multiple clinical settings.